表紙
市場調査レポート

世界の注入型ドラッグデリバリー市場:調製・装置・治療分野別

Injectable Drug Delivery Market by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Global Forecasts to 2017

発行 MarketsandMarkets 商品コード 147604
出版日 ページ情報 英文 369 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
世界の注入型ドラッグデリバリー市場:調製・装置・治療分野別 Injectable Drug Delivery Market by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Global Forecasts to 2017
出版日: 2013年04月03日 ページ情報: 英文 369 Pages
概要

世界の注入型ドラッグデリバリー技術市場額は2012年に225億米ドル額となましたが、2012年から2017年間はCAGR14%の成長が予測され、2017年までに433億米ドル額に達すると予測されています。同市場の成長は、主に製品ライフサイクル管理、技術進歩、製薬市場における生物製剤の急増、世界レベルでの癌・糖尿病発生率の増加、および患者コンプライアンスの改善によってもたらされています。2012年の同市場では地域別で北米が41.3%で最大のシェアを占め、次に欧州の30.2%が続いています)。

当レポートは、世界の注入型ドラッグデリバリー市場の動向と機会、および課題について分析し、装置・調製技術・治療アプリケーション・地域別の市場動向、予測をまとめ、概略以下の構成でお届けいたします。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • イントロダクション
  • 市場セグメント
  • 市場力学
  • 市場シェア分析:主要企業別
    • 従来型注入装置
    • 自己注入装置
      • 無針注射器
      • 自動注射器
      • ペン型注射器

第4章 世界の注入型ドラッグデリバリーデバイス技術別市場

  • イントロダクション
  • 市場セグメント
  • 注入装置メーカーの選定基準
  • 従来の注入型ドラッグデリバリー装置
    • 使いやすさ
    • 素材
    • 製品
  • 自己注入装置
    • 市場セグメント
    • 自己注入装置の選定基準
    • ペン型注射器
    • 無針注射器
    • 自動注射器
  • その他

第5章 世界の注入型ドラッグデリバリー調製技術市場

  • イントロダクション
  • 従来型のドラッグデリバリー
    • 注入ソリューション
    • 再構成/凍結乾燥調製
  • 新しいドラッグデリバリー調製技術
    • 市場セグメント
    • リポソームシステム
    • ミクロスフェア
    • ナノ粒子
    • 高分子ミセル
    • その他

第6章 世界の注入型ドラッグデリバリー技術市場:治療アプリケーション別

  • イントロダクション
  • 自己免疫疾患
    • 多発性硬化症
    • 関節リウマチ
    • クローン病
    • 乾癬
    • その他
  • ホルモン障害
    • 糖尿病
    • 貧血
    • リプロダクティブヘルス疾患
    • 血栓症治療/血栓溶解療法
    • 骨粗しょう症
    • 成長ホルモン欠損症
  • 希少疾患
  • その他
    • 疼痛管理
    • C型肝炎
    • アレルギー
    • 美容

第7章 地域分析

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第8章 競合環境

  • イントロダクション
  • 拡大
  • 合意、提携、協力&ジョイントベンチャー
  • 新製品投入
  • M&A
  • その他の開発
  • 承認

第8章 企業プロファイル(概要・財務・製品&サービス・戦略・開発)

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BT 1862

The injectable drug delivery market is technology driven and is marked by “Threat of Obsolescence” wherein technologies as well as its adoption by patients changes very rapidly.

The industry has seen a shift in paradigm and is now skewed toward self-injection devices that not only cures serious illnesses, but also have fewer serious side effects. The market for injectable drug delivery includes devices and formulations. Traditionally, injectable devices were primarily designed for delivery of insulin and human growth hormones. However, due to technological advancements they are currently being used as combination therapies for the delivery of a wide variety of drug classes such as anticholinergic, hematopoietic, dopamine agonists, parathyroid hormones, reproductive hormones, serotonin antagonists, sympathomimetic and immune modulators.

Self injection devices including auto injectors and pen injectors are the fastest growing segments in the injectable drug delivery market. In recent years, the uptake and adoption of self-injection devices such as auto and pen injectors has grown substantially. This is due to the benefits it offers over conventional injection devices. Self-injection devices ensure better patient adherence to treatment due to decrease risk of missed injection or drug discontinuation, and reduced healthcare cost as costly hospital visits are curtailed. This has ignited the interest of device manufacturers who are in turn incessantly coming up with new variants of self-injection devices with advanced technological features.

Triggered by the upsurge of biologics and injectable drugs, pharmaceutical companies are increasingly adopting and venturing into self injection and microneedles injectable drug delivery technologies. These investments are likely to fortify global foot print of injectable manufacturers, helping them to extend their term of exclusivity for patented drugs with added therapeutic benefits, and to bring up new innovations in injectable devices segment. For instance, in February 2013, SHL Group expanded its auto injector facility in Taiwan with the investment of ~$40 million. The expansion increases the manufacturing capabilities of auto injectors for the firm. Similarly, in January 2012, Clearside Biomedical (an Atlanta-based start up) received $4 million from Hatteras Venture Partners (a venture capital firm in the U.S.) for the development of microinjection technology.

In the coming years, growth of injectable drug delivery market is likely to be hinged at China, India, Brazil, and Mexico. These countries offer an array of opportunities for growth and are likely to serve as revenue pockets for injectable drug delivery technologies market. All these countries offer high growth potential as compared to mature countries such as U.S. and Canada. Growth in these markets is spurred by the growing incidence of diabetes and cancer as the population ages. According to the International Diabetes Federation (IDF), diabetes affects ~285 million people globally, and this number is expected to reach 438 million by 2030, with two-thirds of all diabetes cases in low- to middle-income countries. In addition, British medical journal Lancet states that Asia's cancer rate is projected to reach the figure of 7.1 million new cases by 2020 (an increase of almost 60% compared to 2005). Thus, to meet the increasing demand of injectables for the treatment of chronic diseases in emerging markets, manufacturers are strategically focusing on new product launches, agreements and partnerships, resorting to geographical expansion to increase their market share. Regulatory policies in the Asia-Pacific region are more adaptive and business friendly due to less stringent regulations and less extensive data requirement. Increasing competition in mature markets will further trigger injectable drug delivery technologies manufacturers to focus on emerging markets.

Sustainability of players in highly competitive market is the key challenge that is expected to hinder the growth of the injectable drug delivery market. Injectable drug delivery technologies market is a highly diversified and competitive market with large number of market players including mid-tier firms and start-ups. Players operating in the market strive hard to gain market visibility and a larger market share. Due to high manufacturing cost, marketing and regulatory hurdles for approval of devices, companies struggle to survive and keep pace with the industry's growth. As a result, companies focus on mergers and acquisitions to maintain their sustainability in the market.

The report extensively covers injectable drug delivery market for all major therapeutic areas- both qualitative (technological) and quantitative (revenue) aspects are analyzed at granular level. However, sub-segmentation of the therapeutic market by product type has not been provided as an injection device/formulation technology can be used for various therapeutic indications depending upon the need of the patient. Volume analysis of market has not been provided due to wide variation in prices of devices that varies with different therapeutic indications.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauze the pulse of the market which in turn would help the firms in garnering a greater market share. Firms purchasing the report could use any one or combination of the below mentioned five strategies (Market Penetration, Product Development/Innovation, Market Development, Market Diversification, and Competitive Assessment) for reaping market share.

The report provides insights on the following pointers:

  • Comprehensive information on product portfolio and services offered by the top 20 players in the injectable drug delivery market. The report analyzes the injectable devices and formulations market by category/therapeutic areas across geographies - Market Penetration
  • Detailed insights on upcoming technology, research and developments activities, and new product launches in the injectable drug delivery market - Product Development/Innovation
  • Comprehensive information about lucrative emerging markets. The report analyzes the promising injectable devices and formulations market by category/therapeutic areas across geographies- Market Development
  • Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the injectable drug delivery market - Market Diversification
  • In depth assessment of market share, strategies, products & services, distribution network, manufacturing capabilities of leading players in the injectable drug delivery market -Competitive Assessment

Table of Contents

1. INTRODUCTION

  • 1.1. KEY TAKE-AWAYS
  • 1.2. REPORT DESCRIPTION
  • 1.3. MARKETS COVERED
  • 1.4. STAKEHOLDERS
  • 1.5. RESEARCH METHODOLOGY
    • 1.5.1. MARKET SIZE
    • 1.5.2. MARKET SHARE
    • 1.5.3. KEY DATA POINTS FROM SECONDARY SOURCES
    • 1.5.4. KEY DATA POINTS FROM PRIMARY SOURCES
    • 1.5.5. ASSUMPTIONS

2. EXECUTIVE SUMMARY

3. MARKET OVERVIEW

  • 3.1. INTRODUCTION
  • 3.2. MARKET SEGMENTATION
  • 3.3. MARKET DYNAMICS
    • 3.3.1. DRIVERS
      • 3.3.1.1. Technological Advancements
      • 3.3.1.2. Product Life Cycle Management
      • 3.3.1.3. Surge of Biologics in Pharmaceutical Markets
      • 3.3.1.4. Rising Incidences of Cancer and Diabetes
      • 3.3.1.5. Improving Patient Compliance
    • 3.3.2. RESTRAINTS
      • 3.3.2.1. Regulatory Hurdles
      • 3.3.2.2. Needle-stick Injuries and Infections
      • 3.3.2.3. Development of Alternate Delivery Methods
      • 3.3.2.4. Product Recalls
    • 3.3.3. OPPORTUNITIES
      • 3.3.3.1. Emerging Markets (India, China, Brazil, Mexico and Latin America)
      • 3.3.3.2. Development of Biosimilars in the Pharmaceutical Market
    • 3.3.4. CHALLENGES
      • 3.3.4.1. Sustainability of Players in Highly Competitive Market
  • 3.4. MARKET SHARE ANALYSIS, BY MAJOR PLAYERS
    • 3.4.1. CONVENTIONAL INJECTABLE DEVICES
    • 3.4.2. SELF-INJECTION DEVICES
      • 3.4.2.1. Needle Free Injectors
      • 3.4.2.2. Auto Injectors
      • 3.4.2.3. Pen Injectors

4. GLOBAL INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET

  • 4.1. INTRODUCTION
  • 4.2. MARKET SEGMENTATION
  • 4.3. MANUFACTURERS CRITERIA FOR SELECTION OF AN INJECTABLE DEVICE
  • 4.4. CONVENTIONAL INJECTABLE DRUG DELVERY DEVICES
    • 4.4.1. BY USABILITY
      • 4.4.1.1. Disposable
      • 4.4.1.2. Reusable
    • 4.4.2. BY MATERIAL
      • 4.4.2.1. Glass
      • 4.4.2.2. Plastic
    • 4.4.3. BY PRODUCT
      • 4.4.3.1. Prefilled
      • 4.4.3.2. Fillable
  • 4.5. SELF-INJECTION DEVICES
    • 4.5.1. MARKET SEGMENTATION
    • 4.5.2. SELECTION CRITERIA FOR SELF-INJECTION DEVICE
    • 4.5.3. PEN INJECTORS
      • 4.5.3.1. By Product
        • 4.5.3.1.1. Single chamber pen injectors
        • 4.5.3.1.2. Dual chamber pen injectors
      • 4.5.3.2. By Usability
        • 4.5.3.2.1. Disposable pen injectors
        • 4.5.3.2.2. Reusable pen injectors
      • 4.5.3.3. By Design
        • 4.5.3.3.1. Standard pen injectors
        • 4.5.3.3.2. Customized pen injectors
    • 4.5.4. NEEDLE-FREE INJECTORS
      • 4.5.4.1. By Product
        • 4.5.4.1.1. Prefilled needle free injectors
        • 4.5.4.1.2. Fillable needle free injectors
      • 4.5.4.2. By Technology
        • 4.5.4.2.1. Jet-based needle-free injectors
        • 4.5.4.2.2. Spring-based needle-Free injectors
        • 4.5.4.2.3. Laser-based needle free injectors
        • 4.5.4.2.4. Vibration-based needle free injectors
      • 4.5.4.3. By Usability
        • 4.5.4.3.1. Disposable
        • 4.5.4.3.2. Reusable
    • 4.5.5. AUTO INJECTORS
      • 4.5.5.1. By Product
        • 4.5.5.1.1. Prefilled auto injectors
        • 4.5.5.1.2. Fillable auto injectors
      • 4.5.5.2. By Technology
        • 4.5.5.2.1. Automated auto injectors
        • 4.5.5.2.2. Manual auto injectors
      • 4.5.5.3. By Design
        • 4.5.5.3.1. Standardized auto injectors
        • 4.5.5.3.2. Customized auto injectors
      • 4.5.5.4. By Usability
        • 4.5.5.4.1. Disposable auto injectors
        • 4.5.5.4.2. Reusable auto injectors
  • 4.6. OTHERS

5. GLOBAL INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET

  • 5.1. INTRODUCTION
  • 5.2. CONVENTIONAL DRUG DELIVERY
    • 5.2.1. INJECTABLE SOLUTIONS
    • 5.2.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
  • 5.3. NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES
    • 5.3.1. MARKET SEGMENTATION
    • 5.3.2. LIPOSOMAL SYSTEMS
    • 5.3.3. MICROSPHERES
    • 5.3.4. NANOPARTICLES
    • 5.3.5. POLYMERIC MICELLES
    • 5.3.6. OTHERS

6. GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS

  • 6.1. INTRODUCTION
  • 6.2. AUTO-IMMUNE DISEASES
    • 6.2.1. MULTIPLE SCLEROSIS
    • 6.2.2. RHEUMATOID ARTHRITIS
    • 6.2.3. CROHN'S DISEASES
    • 6.2.4. PSORIASIS
    • 6.2.5. OTHERS
  • 6.3. HORMONAL DISORDERS
    • 6.3.1. DIABETES
    • 6.3.2. ANEMIA
    • 6.3.3. REPRODUCTIVE HEALTH DISEASES
    • 6.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY
    • 6.3.5. OSTEOPOROSIS
    • 6.3.6. GROWTH HORMONE DEFICIENCY
  • 6.4. ORPHAN/RARE DISEASES
  • 6.5. ONCOLOGY
  • 6.6. OTHERS
    • 6.6.1. PAIN MANAGEMENT
    • 6.6.2. HEPATITIS C
    • 6.6.3. ALLERGIES
    • 6.6.4. AESTHETIC TREATMENT

7. GEOGRAPHIC ANALYSIS

  • 7.1. INTRODUCTION
    • 7.1.1. NORTH AMERICA DOMINATES THE MARKET
  • 7.2. NORTH AMERICA
    • 7.2.1. GROWING INCIDENCES OF DIABETES AND DEVELOPMENTS IN NEEDLE FREE TECHNOLOGY DRIVE THE MARKET
    • 7.2.2. NEEDLESTICK INJURIES HAVE BEEN HINDERING THIS MARKET
  • 7.3. EUROPE
    • 7.3.1. LIBERALIZATION OF GENERICS MARKET AND SURGE IN BIOLOGIC HAS BEEN DRIVING THE MARKET
    • 7.3.2. HIGH PRESENCE OF INJECTABLE DRUG DELIVERY MARKET LEADERS DRIVES THE MARKET
    • 7.3.3. HORMONAL DISORDERS HAVE BEEN HIGHLY AFFECTING THE DEMOGRAPHICS IN EUROPE
    • 7.3.4. THE REGION HAS STRICT LEGISLATIONS TO PREVENT RISING INCIDENCES OF NEEDLESTICK INJURIES
  • 7.4. ASIA-PACIFIC
    • 7.4.1. APAC IS THE FASTEST GROWING REGION FOR THIS MARKET
    • 7.4.2. THE REGION EXPERIENCES RISING FOCUS OF VARIOUS GIANT PLAYERS
  • 7.5. ROW
    • 7.5.1. RISING INCIDENCES OF CANCER AND DIABETES AS WELL AS ADAPTIVE REGULATORY POLICIES IS DRIVING THE MARKET
    • 7.5.2. ADAPTIVE REGULATORY POLICIES IN MEXICO & BRAZIL IS SUPPORTING THE MARKET GROWTH

8. COMPETITIVE LANDSCAPE

  • 8.1. INTRODUCTION
  • 8.2. EXPANSION
  • 8.3. AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
  • 8.4. NEW PRODUCT LAUNCH
  • 8.5. MERGERS & ACQUISITIONS
  • 8.6. OTHER DEVELOPMENTS
  • 8.7. APPROVALS

9. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 9.1. ALKERMES, INC.
  • 9.2. ANTARES PHARMA, INC.
  • 9.3. BAXTER INTERNATIONAL, INC.
  • 9.4. BECTON, DICKINSON AND COMPANY
  • 9.5. BESPAK EUROPE, LTD. (SUBSIDIARY OF CONSORT MEDICAL, PLC)
  • 9.6. CROSSJECT
  • 9.7. ELCAM MEDICAL
  • 9.8. ELI LILLY AND COMPANY
  • 9.9. GERRESHEIMER AG
  • 9.10. HASELMEIER GMBH
  • 9.11. INJEX PHARMA GMBH (SUBSIDIARY OF HNS INTERNATIONAL, INC.)
  • 9.12. NOVO NORDISK A/S
  • 9.13. OWEN MUMFORD, LTD.
  • 9.14. SANOFI
  • 9.15. SCHOTT AG
  • 9.16. SHL GROUP
  • 9.17. TERUMO CORPORATION
  • 9.18. UNILIFE CORPORATION
  • 9.19. VETTER PHARMA-FERTIGUNG GMBH & CO. KG
  • 9.20. WEST PHARMACEUTICAL SERVICES, INC.
  • 9.21. YPSOMED HOLDING AG
  • 9.22. ZOGENIX, INC.

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

LIST OF TABLES

  • TABLE 1. GLOBAL INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 - 2017 ($BILLION)
  • TABLE 2. GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 - 2017 ($BILLION)
  • TABLE 3. INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 4. GLOBAL INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY PRODUCT, 2010 - 2017 ($BILLION)
  • TABLE 5. INJECTION DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 6. CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 7. GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2010 - 2017 ($BILLION)
  • TABLE 8. DISPOSABLE CONVENTIONAL DEVICES MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 9. REUSABLE CONVENTIONAL DEVICES MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 10. GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2010 - 2017 ($BILLION)
  • TABLE 11. CONVENTIONAL INJECTION DEVICES (GLASS) MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 12. CONVENTIONAL INJECTION DEVICES (PLASTIC) MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 13. GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2010 - 2017 ($BILLION)
  • TABLE 14. PREFILLED CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 15. FILLABLE CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 16. MAJOR THERAPEUTIC AREAS FOR SELF-INJECTION DEVICES
  • TABLE 17. GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 - 2017 ($BILLION)
  • TABLE 18. SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 19. PEN INJECTOR MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 20. GLOBAL PEN INJECTORS MARKET, BY PRODUCT, 2010 - 2017 ($MILLION)
  • TABLE 21. SINGLE CHAMBER PEN INJECTOR MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 22. DUAL CHAMBER PEN INJECTOR MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 23. GLOBAL PEN INJECTORS MARKET, BY USABILITY, 2010 - 2017 ($MILLION)
  • TABLE 24. DISPOSABLE PEN INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 25. REUSABLE PEN INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 26. GLOBAL PEN INJECTORS MARKET, BY DESIGN, 2010 - 2017 ($MILLION)
  • TABLE 27. STANDARD PEN INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 28. CUSTOMIZED PEN INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 29. NEEDLE FREE INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 30. GLOBAL NEEDLE FREE INJECTORS MARKET, BY PRODUCT, 2010 - 2017 ($MILLION)
  • TABLE 31. PREFILLED NEEDLE FREE INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 32. FILLABLE NEEDLE FREE INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 33. GLOBAL NEEDLE FREE INJECTORS MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 34. JET-BASED NEEDLE FREE INJECTOR MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 35. SPRING-BASED NEEDLE FREE INJECTOR MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 36. LASER-POWERED NEEDLE FREE INJECTOR MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 37. VIBRATION-BASED NEEDLE FREE INJECTOR MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 38. GLOBAL NEEDLE FREE INJECTORS MARKET, BY USABILITY, 2010 - 2017 ($MILLION)
  • TABLE 39. DISPOSABLE NEEDLE FREE INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 40. REUSABLE NEEDLE FREE INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 41. AUTO INJECTORS PRODUCTS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 42. GLOBAL AUTO INJECTORS MARKET, BY PRODUCT, 2010 - 2017 ($MILLION)
  • TABLE 43. PREFILLED AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 44. FILLABLE AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 45. GLOBAL AUTO INJECTORS MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 46. AUTOMATED AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 47. MANUAL AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 48. GLOBAL AUTO INJECTORS MARKET, BY DESIGN, 2010 - 2017 ($MILLION)
  • TABLE 49. STANDARDIZED AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 50. CUSTOMIZED AUTO INJECTORS AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 51. GLOBAL AUTO INJECTORS MARKET, BY USABILITY, 2010 - 2017 ($MILLION)
  • TABLE 52. DISPOSABLE AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 53. REUSABLE AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 54. OTHERS INJECTORS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 55. GLOBAL INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY SEGMENT, 2010 - 2017 ($BILLION)
  • TABLE 56. INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 57. GLOBAL CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 - 2017 ($BILLION)
  • TABLE 58. CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 59. INJECTABLE SOLUTIONS CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 60. RECONSTITUTED/LYOPHILIZED CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 61. NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 - 2017 ($BILLION)
  • TABLE 62. NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 63. LIPOSOME DRUG DELIVEY FORMULATION MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 64. MICROSPHERES DRUG DELIVEY FORMULATION MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 65. NANOPARTICLES DRUG DELIVEY FORMULATION MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 66. POLYMERIC MICELLES DRUG DELIVEY FORMULATION MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 67. OTHERS NOVEL DRUG DELIVEY FORMULATION MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 68. GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS, 2010 - 2017 ($MILLION)
  • TABLE 69. GLOBAL AUTO-IMMUNE THERAPEUTIC MARKET, BY INDICATION, 2010 - 2017 ($MILLION)
  • TABLE 70. AUTO-IMMUNE THERAPEUTIC MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 71. MULTIPLE SCLEROSIS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 72. RHEUMATOID ARTHRITIS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 73. CROHN'S DISEASES MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 74. PSORIASIS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 75. OTHER AUTO-IMMUNE DISEASES MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 76. GLOBAL HORMONAL DISORDERS, BY INDICATION, 2010 - 2017 ($MILLION)
  • TABLE 77. HORMONAL DISORDERS MARKET, BY GEOGRAPHY, 2010 - 2017($BILLION)
  • TABLE 78. DIABETES MARKET, BY GEOGRAPHY, 2010 - 2017 ($BILLION)
  • TABLE 79. ANEMIA MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 80. REPRODUCTIVE HEALTH DISEASES MARKET, BY GEOGRAPHY, 2010 - 2017($MILLION)
  • TABLE 81. ANTITHROMBOTIC THERAPY MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 82. OSTEOPOROSIS MARKET, BY GEOGRAPHY, 2010 - 2017($MILLION)
  • TABLE 83. GROWTH HORMONE DEFICIENCY MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 84. ORPHAN/RARE DISEASES THERAPEUTIC MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 85. ONCOLOGY THERAPEUTIC MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 86. GLOBAL OTHER THERAPEUTIC MARKET, 2010 - 2017 ($MILLION)
  • TABLE 87. OTHER THERAPEUTIC MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 88. PAIN MANAGEMENT MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 89. HEPATITIS C MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 90. ALLERGIES/ANAPHYLYTIC SHOCK MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 91. AESTHETIC TREATMENT MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)
  • TABLE 92. NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET,2010 - 2017 ($BILLION)
  • TABLE 93. NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY SEGMENT, 2010 - 2017 ($BILLION)
  • TABLE 94. NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 - 2017 ($BILLION)
  • TABLE 95. NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION 2010 - 2017 ($BILLION)
  • TABLE 96. EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, 2010 - 2017 ($BILLION)
  • TABLE 97. EUROPE: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, 2010 - 2017 ($MILLION)
  • TABLE 98. EUROPE INJECTABLE DRUG DELIVERY FORMULATIONS TECHNOLOGIES MARKET, BY SEGMENT, 2010 - 2017 ($BILLION)
  • TABLE 99. EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICTION, 2010 - 2017 ($BILLION)
  • TABLE 100. APAC: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT,2010 - 2017 ($BILLION)
  • TABLE 101. APAC: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY SEGMENT, 2010 - 2017 ($MILLION)
  • TABLE 102. APAC: INJECTABLE DRUG DELIVERY FORMULATIONS TECHNOLOGIES MARKET, BY SEGMENT, 2010 - 2017 ($BILLION)
  • TABLE 103. APAC: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION, 2010 - 2017 ($MILLION)
  • TABLE 104. ROW: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 - 2017 ($MILLION)
  • TABLE 105. ROW: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY SEGMENT, 2010 - 2017 ($MILLION)
  • TABLE 106. ROW: INJECTABLE DRUG DELIVERY FORMULATIONS TECHNOLOGIES MARKET, BY SEGMENT, 2010 - 2017 ($MILLION)
  • TABLE 107. ROW: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION, 2010 - 2017 ($MILLION)
  • TABLE 108. EXPANSION, 2010 - 2013
  • TABLE 109. AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 - 2013
  • TABLE 110. NEW PRODUCT LAUNCH, 2010 - 2013
  • TABLE 111. MERGERS & ACQUISITIONS, 2010 - 2013
  • TABLE 112. OTHER DEVELOPMENTS, 2010 - 2013
  • TABLE 113. APPROVALS, 2010 - 2013
  • TABLE 114. ALKERMES: TOTAL REVENUE AND R&D EXPENSES, 2009- 2011 ($MILLION)
  • TABLE 115. ALKERMES: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
  • TABLE 116. ANTARES PHARMA: TOTAL REVENUES AND R&D EXPENDITURE, 2010 - 2012 ($MILLION)
  • TABLE 117. ANTARES PHARMA: TOTAL REVENUE, BY GEOGRAPHY, 2010 - 2012 ($MILLION)
  • TABLE 118. ANTARES PHARMA: TOTAL REVENUE, BY PRODUCT, 2010 - 2012 ($MILLION)
  • TABLE 119. BAXTER INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, 2010 - 2012 ($MILLION)
  • TABLE 120. BAXTER INTERNATIONAL: TOTAL REVENUE, BY SEGMENT, 2010 - 2012 ($MILLION)
  • TABLE 121. BAXTER INTERNATIONAL: MEDICAL PRODUCTS TOTAL REVENUE, 2010 - 2012($MILLION)
  • TABLE 122. BAXTER INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY, 2010 - 2012 ($MILLION)
  • TABLE 123. BECTON DICKINSON: TOTAL REVENUES & R&D EXPENDITURE, 2010 - 2012 ($MILLION)
  • TABLE 124. BECTON DICKINSON: TOTAL REVENUE, BY SEGMENT, 2010 - 2012 ($MILLION)
  • TABLE 125. BECTON DICKINSON: MEDICAL DIVISION TOTAL REVENUE, 2010 - 2012 ($MILLION)
  • TABLE 126. BECTON DICKINSON: TOTAL REVENUE, BY GEOGRAPHY, 2010- 2012 ($MILLION)
  • TABLE 127. CONSORT MEDICAL: TOTAL REVENUE AND R&D EXPENSE, 2009 - 2011 ($MILLION)
  • TABLE 128. CONSORT MEDICAL: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
  • TABLE 129. ELI LILLY & CO: TOTAL REVENUE AND R&D EXPENSES, 2010 - 2012 ($BILLION)
  • TABLE 130. ELI LILLY & CO: TOTAL REVENUE, BY SEGMENT, 2010 - 2012 ($BILLION)
  • TABLE 131. ELI LILLY & CO: TOTAL REVENUE BY GEOGRAPHY, 2010 - 2012 ($BILLION)
  • TABLE 132. GERRESHEIMER AG: TOTAL REVENUE AND R&D EXPENSES, 2010 - 2012 ($MILLION)
  • TABLE 133. GERRESHEIMER AG: TOTAL REVENUE, BY SEGMENT, 2010 - 2012 ($MILLION)
  • TABLE 134. GERRESHEIMER AG: TOTAL REVENUE, BY GEOGRAPHY, 2010 - 2012 ($MILLION)
  • TABLE 135. NOVO NORDISK: TOTAL REVENUE AND R&D EXPENSES, 2010 - 2012 ($BILLION)
  • TABLE 136. NOVO NORDISK: TOTAL REVENUE, BY SEGMENT, 2010 - 2012 ($BILLION)
  • TABLE 137. NOVO NORDISK: TOTAL REVENUE, BY GEOGRAPHY, 2010 - 2012 ($BILLION)
  • TABLE 138. SANOFI: TOTAL REVENUE & R&D EXPENDITURE, 2010 - 2012 ($BILLION)
  • TABLE 139. SANOFI: TOTAL REVENUE, BY SEGMENT, 2010 - 2012 ($BILLION)
  • TABLE 140. SANOFI: TOTAL REVENUE, BY GEOGRAPHY, 2010 - 2012 ($BILLION)
  • TABLE 141. SCHOTT AG: TOTAL REVENUE AND R&D EXPENDITURES, 2010 - 2012 ($MILLION)
  • TABLE 142. SCHOTT AG: TOTAL REVENUE, BY GEOGRAPHY, 2010 - 2012 ($MILLION)
  • TABLE 143. TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
  • TABLE 144. TERUMO CORPORATION: TOTAL REVENUE, BY SEGMENT, 2009 - 2011 ($MILLION)
  • TABLE 145. TERUMO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
  • TABLE 146. UNILIFE CORPORATION: TOTAL REVENUE AND R&D EXPENDITURE, 2010 - 2012 ($MILLION)
  • TABLE 147. UNILIFE CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2010 - 2012 ($MILLION)
  • TABLE 148. WEST PHARMA: TOTAL REVENUES AND R&D EXPENSES, 2010 - 2012 ($MILLION)
  • TABLE 149. WEST PHARMA: TOTAL REVENUE, BY SEGMENT, 2010 - 2012 ($MILLION)
  • TABLE 150. WEST PHARMA: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2012 ($MILLION)
  • TABLE 151. YPSOMED: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
  • TABLE 152. YPSOMED: TOTAL REVENUE, BY SEGMENT, 2009 - 2011 ($MILLION)
  • TABLE 153. YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2009 ($MILLION)
  • TABLE 154. YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2010 - 2011 ($MILLION)
  • TABLE 155. ZOGENIX, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2010 - 2012 ($MILLION)

LIST OF FIGURES

  • FIGURE 1. GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2012 & 2017
  • FIGURE 2. INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2012
  • FIGURE 3. INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION
  • FIGURE 4. INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION
  • FIGURE 5. MARKET SEGMENTATION OF INJECTABLE DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATION
  • FIGURE 6. INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET DYNAMICS
  • FIGURE 7. GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY KEY PLAYERS, 2012 ($MILLION)
  • FIGURE 8. GLOBAL SELF-INJECTION DEVICES MARKET, BY KEY PLAYERS, 2012 ($MILLION)
  • FIGURE 9. GLOBAL NEEDLE FREE INJECTOR MARKET, BY KEY PLAYERS, 2012 ($MILLION)
  • FIGURE 10. GLOBAL AUTO INJECTOR MARKET, BY KEY PLAYERS, 2012 ($MILLION)
  • FIGURE 11. GLOBAL PEN INJECTOR MARKET, BY KEY PLAYERS, 2012 ($MILLION)
  • FIGURE 12. INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET SEGMENTATION
  • FIGURE 13. FACTORS AFFECTING SELECTION OF AN INJECTABLE DEVICE
  • FIGURE 14. GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 - 2017 ($BILLION)
  • FIGURE 15. SELF-INJECTION DEVICES MARKET SEGMENTATION
  • FIGURE 16. FACTORS AFFECTING SELECTION OF SELF-INJECTION DEVICE
  • FIGURE 17. CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET SEGMENTATION
  • FIGURE 18. GLOBAL NOVEL DRUG DELIVEY FORMULATION MARKET, 2012 & 2017 ($BILLION)
  • FIGURE 19. NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES SEGMENTATION
  • FIGURE 20. GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION, 2010 - 2017 ($BILLION)
  • FIGURE 21. INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION, BY THERAPEUTIC APPLICATIONS
  • FIGURE 22. AUTO-IMMUNE THERAPEUTIC MARKET SEGMENTATION
  • FIGURE 23. HORMONAL DISORDERS MARKET SEGMENTATION
  • FIGURE 24. INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2012 - 2017 ($BILLION)
  • FIGURE 25. KEY GROWTH STRATEGIES, 2010 - 2013
  • FIGURE 26. KEY PLAYERS FOCUSING ON EXPANSION, 2010 - 2013
  • FIGURE 27. KEY PLAYERS FOCUSING ON AGREEMENTS, PARTNERSHIPS, COLLABORATIONS AND JOINT VENTURES, 2010 - 2013
Back to Top